



Caprion Biosciences to Present Two Posters at the Annual PEGS Conference in Boston

Posters to Highlight Novel Mass Spectrometry methods for Identification and Quantification of Host Cell Proteins and Direct Identification of Neo-Epitopes in Tumor Tissue

Montreal, Canada – April 26, 2016— Caprion announced today that Dr. Diane McCarthy, Sr. Scientific Director will present two posters on novel applications of Caprion's ProteoCarta™ Technology platform at the Annual PEGS Protein Engineering Summit to be held in Boston from April 25-29, 2016. The first poster will present data on the application of mass spectrometry for identification and quantification of host cell proteins (HCP) that co-purify with biologics. The case study will show how Caprion's ProteoCarta™ Technology can directly detect proteins without antibodies or gel separation after manufacturing in CHO, E. coli, and yeast and how this approach can be used directly to compare purity of different biologics manufacturing process batches, monitor batch uniformity, or compare different production sites. The assay can be deployed using a targeted multiple reaction monitoring (MRM) approach to quantify hundreds of peptide/protein of interest. The second poster features a new method developed using Caprion's ProteoCarta™ Technology platform for the direct detection of naturally-processed peptides presented by MHC in tumor tissue. This new method accelerates development of therapeutic cancer vaccines and adoptive T-cell therapies by rapidly and systematically identifying neo-epitopes that are unique or highly upregulated in cancer tissue.

Poster #1 Title: Identification and Quantification of Host Cell Proteins by Mass Spectrometry

Time: Tuesday April 26, 10:00am- 4:30pm

Poster #2 Title: Direct Identification of Neo-Epitopes in Tumor Tissue

Time: Wednesday and Thursday, April 27th -28th 10:00am- 5:00pm

About Caprion Biosciences, Inc.

Caprion is the leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Caprion's immune monitoring division, ImmuneCarta®, offers proprietary multiparametric flow cytometry services for functional analyses of innate and adaptive immune responses. Caprion's proteomics division, ProteoCarta™, offers proprietary gel-free, label-free mass spectrometry (MS) for comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers. Caprion also leverages ProteoCarta and ImmuneCarta to develop its own in-vitro diagnostic products targeting cancer, metabolic and infectious diseases. Based in Montreal, Canada, Caprion has been providing large-

scale proteomics and immune monitoring services to over 50 major pharmaceutical and biotech clients for more than 12 years. Caprion, a privately-held company, is majority owned by Chicago Growth Partners. For more information, please visit www.caprion.com.

Media Contact
Carol Berry
Chief Business Officer, SVP
Caprion Bioscience
cberry@caprion.com
514.360.3600